Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.55 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.37 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octane SCHEMBL6697448 | 0.88 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRNA7L3MBTL4L3MBTL3 | |
| SCHEMBL5389893 | 0.80 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL5382193 | 0.79 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL8134466 | 0.74 | CHRNB2 (0.41) | CHRNB2CHRNA4L3MBTL4L3MBTL3L3MBTL1 | |
| SCHEMBL7225743 | 0.73 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL7221390 | 0.73 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL3058805 | 0.72 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL17264284 | 0.72 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL3058809 | 0.72 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL5382186 | 0.72 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118666833-B | Preparation method of 2- (5-bromopyridine-3-yl) quinuclidine | 龙曦宁（上海）医药科技有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-118666833-A | Preparation method of 2- (5-bromopyridine-3-yl) quinuclidine | 龙曦宁（上海）医药科技有限公司 | 2024-09-20 | — | — | CN | claimed |
| US-6624173-B1 | Characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) treated by | TARGACEPT, INC. | 2003-09-23 | — | — | US | claimed |
| CN-118666833-B | Preparation method of 2- (5-bromopyridine-3-yl) quinuclidine | 龙曦宁（上海）医药科技有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118666833-B | Preparation method of 2- (5-bromopyridine-3-yl) quinuclidine | 龙曦宁（上海）医药科技有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118666833-B | Preparation method of 2- (5-bromopyridine-3-yl) quinuclidine | 龙曦宁（上海）医药科技有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118666833-A | Preparation method of 2- (5-bromopyridine-3-yl) quinuclidine | 龙曦宁（上海）医药科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-118666833-A | Preparation method of 2- (5-bromopyridine-3-yl) quinuclidine | 龙曦宁（上海）医药科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-118666833-A | Preparation method of 2- (5-bromopyridine-3-yl) quinuclidine | 龙曦宁（上海）医药科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20070185086-A1 | Pharmaceutical Compositions and Methods for Effecting Dopamine Release | BENCHERIF MEROUANE | 2007-08-09 | — | — | US | disclosed |
| US-7214686-B2 | Pharmaceutical compositions and methods for effecting dopamine release | TARGACEPT, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| WO-2004108668-A2 | ALPHA-7 NEURONAL NICOTINIC RECEPTOR LIGANDS: COMPOSITIONS AND METHODS OF USE | TARGACEPT, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040220214-A1 | Pharmaceutical compositions and methods for effecting dopamine release | TARGACEPT, INC. | 2004-11-04 | — | — | US | disclosed |
| EP-0994875-B1 | 3-PYRIDYL-1-AZABICYCLOALKANE DERIVATIVES FOR PREVENTION AND TREATMENT OF CNS DISORDERS | TARGACEPT INC (US) | 2004-03-10 | — | — | EP | disclosed |
| US-6624173-B1 | Characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) treated by | TARGACEPT, INC. | 2003-09-23 | — | — | US | disclosed |
| US-6525065-B1 | Central nervous system disorders; administering an endo or exo form of a 1-aza-2-(3-pyridyl)bicyclo(2.2.1)heptane, or a 1-aza-7-(3-pyridyl)bicyclo(3.2.2) nonane, or a 1-aza-2-(3-pyridyl)bicyclo(2.2.2)octane | TARGACEPT, INC. | 2003-02-25 | — | — | US | disclosed |
| EP-0994875-A1 | 3-PYRIDYL-1-AZA-BICYCLO-ALKANE DERIVATIVES FOR PREVENTION AND TREATMENT OF CNS DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999000385-A1 | 3-PYRIDYL-1-AZA-BICYCLO-ALKANE DERIVATIVES FOR PREVENTION AND TREATMENT OF CNS DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220214-A1 | Pharmaceutical compositions and methods for effecting dopamine release | COMT, SLC6A3, PARK7 | CHRNB2 16/4885CHRNA4 74/4885CHRNA7 27/4885 |
| US-20070185086-A1 | Pharmaceutical Compositions and Methods for Effecting Dopamine Release | COMT, SLC6A3, HTR2A | CHRNB2 22/4885CHRNA4 82/4885CHRNA7 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.